Pharsight

Katerzia generic

Katerzia is an anti-hypertensive drug owned by Azurity. This drug contains an active ingredient, amlodipine benzoate, and it is available in suspension;oral dosage forms. Katerzia was first authorised for market use on 08 July, 2019, and it currently holds a total of 9 drug patents, none of which have expired.

When will Katerzia generic be available?

The generic version of Katerzia could be released after 11 April, 2039, which is the expiry date of its last patent. The date reflects the expiry date of the drug's last patent and is usually tied to a Para IV filing.

Katerzia uses

Katerzia is effectively used for treating various heart and blood pressure conditions. These uses comprise angina pectoris, a type of angina and a method of treating coronary artery disease. Moreover, it is widely utilized as a treatment and method of treating hypertension, primarily attributable to its active ingredient, amlodipine benzoate.

Katerzia patent expiration

Katerzia holds a total of 9 patents, all of which cover amlodipine formulations. The last patent of this Katerzia generic possibly expires on 11 April, 2039. The patents ensure the drug's market exclusivity until the mentioned dates. Below are the details of the patent:

Katerzia dosage

Want to ask something?